Disc Medicine (IRON) Competitors $49.42 +2.27 (+4.81%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRON vs. LEGN, SRPT, TLX, ADMA, BPMC, VRNA, NUVL, AXSM, GRFS, and CYTKShould you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), ADMA Biologics (ADMA), Blueprint Medicines (BPMC), Verona Pharma (VRNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Grifols (GRFS), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Disc Medicine vs. Legend Biotech Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares ADMA Biologics Blueprint Medicines Verona Pharma Nuvalent Axsome Therapeutics Grifols Cytokinetics Disc Medicine (NASDAQ:IRON) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment. Do analysts rate IRON or LEGN? Disc Medicine presently has a consensus price target of $93.80, suggesting a potential upside of 89.80%. Legend Biotech has a consensus price target of $78.82, suggesting a potential upside of 125.52%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has stronger earnings & valuation, IRON or LEGN? Disc Medicine has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$76.43M-$3.99-12.39Legend Biotech$627.24M10.23-$518.25M-$0.48-72.81 Is IRON or LEGN more profitable? Disc Medicine has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Disc Medicine's return on equity of -25.24% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -25.24% -23.96% Legend Biotech -66.92%-29.69%-19.45% Which has more risk & volatility, IRON or LEGN? Disc Medicine has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Does the MarketBeat Community favor IRON or LEGN? Legend Biotech received 32 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 86.57% of users gave Disc Medicine an outperform vote while only 72.58% of users gave Legend Biotech an outperform vote. CompanyUnderperformOutperformDisc MedicineOutperform Votes5886.57% Underperform Votes913.43%Legend BiotechOutperform Votes9072.58% Underperform Votes3427.42% Do institutionals & insiders have more ownership in IRON or LEGN? 83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 4.2% of Disc Medicine shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to IRON or LEGN? In the previous week, Legend Biotech had 1 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for Legend Biotech and 8 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 1.55 beat Legend Biotech's score of 1.25 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Legend Biotech 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDisc Medicine beats Legend Biotech on 11 of the 18 factors compared between the two stocks. Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRON vs. The Competition Export to ExcelMetricDisc MedicinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$6.89B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-12.427.4422.4418.48Price / SalesN/A242.66394.66103.91Price / CashN/A65.8538.1834.62Price / Book3.496.516.774.25Net Income-$76.43M$143.21M$3.22B$248.23M7 Day Performance9.46%3.97%3.09%3.29%1 Month Performance-5.61%0.37%-0.14%2.43%1 Year Performance77.51%2.59%17.98%5.54% Disc Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRONDisc Medicine2.3669 of 5 stars$49.42+4.8%$93.80+89.8%+77.5%$1.71BN/A-12.4230Upcoming EarningsNews CoveragePositive NewsLEGNLegend Biotech2.6249 of 5 stars$34.70+1.2%$78.82+127.1%-20.1%$6.37B$627.24M-36.531,070SRPTSarepta Therapeutics4.7326 of 5 stars$61.51+1.8%$158.70+158.0%-50.7%$5.97B$1.90B49.21840TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.57-6.5%$22.00+25.2%N/A$5.94B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownHigh Trading VolumeADMAADMA Biologics1.4801 of 5 stars$24.51+12.1%$22.50-8.2%+265.0%$5.82B$426.45M87.54530Upcoming EarningsNews CoveragePositive NewsGap DownHigh Trading VolumeBPMCBlueprint Medicines2.5608 of 5 stars$88.51+1.0%$124.53+40.7%-2.0%$5.66B$508.82M-81.95640Analyst ForecastPositive NewsVRNAVerona Pharma2.9049 of 5 stars$68.83+5.1%$78.50+14.0%+366.5%$5.56B$42.28M-35.8530Earnings ReportAnalyst ForecastShort Interest ↓News CoveragePositive NewsNUVLNuvalent1.8884 of 5 stars$75.20+2.3%$115.50+53.6%+11.4%$5.38BN/A-21.6740Upcoming EarningsPositive NewsAXSMAxsome Therapeutics4.8344 of 5 stars$107.24+0.9%$169.80+58.3%+52.2%$5.23B$385.69M-17.90380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsGRFSGrifols3.8779 of 5 stars$7.15-0.8%N/A+8.1%$4.92B$7.21B6.1126,300Short Interest ↓Positive NewsCYTKCytokinetics4.2611 of 5 stars$41.22+2.0%$79.13+92.0%-30.1%$4.91B$18.47M-7.66250Upcoming EarningsInsider Trade Related Companies and Tools Related Companies Legend Biotech Alternatives Sarepta Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives ADMA Biologics Alternatives Blueprint Medicines Alternatives Verona Pharma Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Grifols Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRON) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IRON Stock Free IRON Stock Alerts